disease

Metabolon’s Untargeted Metabolomics Services Used for Breakthrough Study Revealing Powerful Link Between Gut Microbiome, the Metabolome, and Type 2 Diabetes (T2D)

Combining metabolomics, gut microbiome, and clinical data may help prevent and personalize the treatment of type 2 diabetes MORRISVILLE, N.C.,…

1 month ago

GE HealthCare drives innovation in theranostics with latest technological advances

GE HealthCare is helping advance clinical and operational excellence in theranostics and molecular imaging through a comprehensive portfolio of AI-powered…

2 months ago

Novo Nordisk: Higher dose of Wegovy provided average weight loss of 21% in people with obesity with a third achieving 25% or more according to data presented at ADA

Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25%…

2 months ago

Peer-Reviewed Study in Nature Scientific Reports Demonstrates Non-Invasive Fat Reduction Using Alma’s Energy-Based Technology

CAESAREA, Israel, June 17, 2025 /PRNewswire/ -- A newly published, peer-reviewed study in Nature Scientific Reports, part of the prestigious Nature…

2 months ago

Roche to advance prasinezumab into Phase III development for early-stage Parkinson’s disease

Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage…

2 months ago

GLOBAL MANCOZEB SUMMIT: ADDRESSING ITS CRUCIAL ROLE IN CROP PROTECTION AHEAD OF EU COURT HEARING

LONDON, June 16, 2025 /PRNewswire/ -- UPL Corporation Ltd. (UPL Corp) - part of UPL Group Company (NSE: UPL) & (BSE:…

2 months ago

Investigational combination of first-in-class bispecific antibodies TALVEY (talquetamab) and TECVAYLI (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of…

2 months ago

Merry Life Launches Global Phase II Trial of TML-6, The First Drug Targeted at Autolysosome pathway for Therapy of Alzheimer’s Disease

TAINAN, June 13, 2025 /PRNewswire/ -- Merry Life Biomedical Company announces the launch of its global Phase II clinical trial…

2 months ago

Bay Area Lyme Foundation Announces National Winner of the 2025 Emerging Leader Award to Develop a Much-Needed Rapid, Low-Cost, Easy-to-Use Lyme Disease Test

PORTOLA VALLEY, Calif., June 12, 2025 (GLOBE NEWSWIRE) -- Bay Area Lyme Foundation, a leading sponsor of Lyme disease research…

2 months ago

Alamar Biosciences, Alzheimer’s Disease Data Initiative, and Gates Ventures Unite in Global Partnership to Advance Translational Research in Alzheimer’s Disease.

Multi-center project will profile over 40,000 samples using ultra-sensitive NULISA™ technology. FREMONT, Calif., June 10, 2025 /PRNewswire/ -- Alamar Biosciences,…

2 months ago